Evidence map›Paper›PMID 39957412›Full record

ArticleAnnals of clinical and translational neurology2025

High-Throughput Immunoassays for Cavin-4 IgG: A Diagnostic Tool for Immune-Mediated Rippling Muscle Disease.

Reghann G LaFrance-Corey, Haidara Kherbek, Nimalan Harinesan, Margherita Milone, Naveen K Paramasivan, Pallab Sarker, Andrew M Knight, Carley Karsten, Surendra Dasari, Teerin Liewluck and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Reghann G LaFrance-CoreyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Haidara KherbekDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0263-0378
Nimalan HarinesanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Margherita MiloneDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4338-9007
Naveen K ParamasivanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Pallab SarkerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Andrew M KnightDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Carley KarstenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Surendra DasariDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Teerin LiewluckDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
William J LitchyDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Sean J PittockDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6140-5584
John R MillsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Divyanshu DubeyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4302-4075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cavin-4 was identified as a potential autoantigen for immune-mediated rippling muscle disease (iRMD). To validate this, we developed and tested various immunoassays, including a cell-based assay (CBA), cavin-4 recombinant protein ELISA, and multi-peptide ELISA. Among 19 iRMD patients, all exhibited muscle rippling, and 13 had percussion-induced mounding. All immunoassays demonstrated clinical and analytical specificities greater than 95%. The protein ELISA had the highest sensitivity (94.7%) and specificity (99.9%), outperforming CBA (sensitivity 89.5%, specificity 99.6%) and the multi-peptide ELISA (sensitivity 79.0%, specificity 97.2%). Our results suggest that the cavin-4 protein ELISA is a promising tool for high-throughput clinical testing in iRMD.

Indexed as

AutoantigensHigh-Throughput Screening AssaysImmunoglobulin GMuscular DiseasesAdolescentAdultAutoantibodiesChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoassayMaleMiddle AgedSensitivity and SpecificityAutoantibodiesAutoantigensImmunoglobulin Gautoimmune myopathycaveolae‐associated protein 4 (cavin‐4)enzyme‐linked immunosorbent assay (ELISA)immune‐mediated rippling muscle disease (iRMD)phage immunoprecipitation sequencing (PhIP‐Seq)

Identifiers

PMID39957412
PMCPMC12040518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.